PharmAthene Awarded for Advanced Development of Protexia(R)
First Recombinant BChE to Meet Department of Defense Selection Criteria
ANNAPOLIS, Md., Sept 25, 2006 /PRNewswire via COMTEX/ -- PharmAthene, Inc., a leading biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological terrorism, announced today that it has been awarded a multi-year contract valued at up to $213 million from the Department of Defense (DoD) U.S. Army Space and Missile Command, for advanced development of the Company's broad spectrum chemical nerve agent prophylaxis, Protexia(R). "We are extremely pleased to have been chosen by the Department of Defense as the recipient of this important biodefense contract," commented David P. Wright, President and Chief Executive Officer of PharmAthene. "The Department of Defense continues to be at the forefront of the development and procurement of novel therapeutic countermeasures to combat chemical and biological warfare and we are very excited to partner with them to carry out advanced development of Protexia."
Under the contract, PharmAthene will be responsible for the conduct and oversight of all product development activities. The initial stage of development, for which $34.7 million has been allocated, includes manufacturing process development, preclinical safety and toxicity testing, submission of an Investigational New Drug (IND) Application with the United States Food and Drug Administration (FDA), and initiation of a Phase I clinical trial. Following the successful completion of the Phase I clinical trial, the government may exercise its option to fund additional development activities beyond the initial $34.7 million, leading to FDA licensure. The contract also provides the Department of Defense with the option to procure an initial 90,000 doses of Protexia.
"Today's announcement highlights the intense commitment and strong technical capability PharmAthene has demonstrated in assembling and rapidly advancing a comprehensive portfolio of biodefense-focused therapeutics to meet the urgent biosecurity needs of our nation and allies," said Mr. Wright. "Since our acquisition of Protexia last year, we have made rapid progress defining a viable manufacturing process for commercial scale production and demonstrated proof of concept showing protection with Protexia against highly lethal doses of nerve agent exposure. Our proven internal expertise in drug development, in combination with the funding provided under the DoD contract, will significantly enhance our ability to ensure that Protexia becomes an important part of the nation's military and civilian biodefense arsenal."
Mr. Wright continued, "Upon the completion of our proposed merger with SIGA Technologies, Inc., we believe PharmAthene will have one of the broadest portfolios in biodefense with three best-in-class products targeting the highest priority threat assessments identified by the U.S. Government. In addition to Protexia, our post-merger portfolio will include Valortim(TM), for the prevention and treatment of anthrax infection, and ST-246, a small molecule, orally-active antiviral therapeutic for the treatment of smallpox and other orthopox virus infections. We look forward to completing the merger with SIGA and making progress advancing each of these important products."
The Protexia contract was awarded through a full and open competitive solicitation seeking novel second generation prophylactic products for use in humans to prevent and treat poisoning from organophosphorus (OP) nerve agents such as sarin gas, soman, tabun and VX. Protexia is a form of recombinant human butyrylcholinesterase (rBChE), a potent organophosphorus (OP) scavenger protein, being developed for use as a prophylactic to protect U.S. military personnel and civilians from the toxic effects of chemical nerve agents.
"In collaboration with the United States Army Medical Research Institute of Chemical Defense (USAMRICD) and DRDC Suffield we have amassed an impressive collection of data which supports the superior benefit of rBChE in the prevention and treatment of nerve agent toxicity," said Dr. Solomon Langermann, Vice President and Chief Scientific Officer of PharmAthene. "Preclinical studies suggest that in contrast to currently available treatments, rBChE can provide protection against both the physiological and neurological toxicities associated with nerve agent poisoning. In addition, our proprietary manufacturing method enables substantially larger production yields than what is possible with human plasma-derived BChE, suggesting that when developed, Protexia (rBChE) can adequately fulfill the U.S. military and civilian stockpile requirements. It is these unique characteristics which make Protexia the superior choice for military and civilian chemical defense and we look forward to continuing our collaborative work with DoD."
This communication is being made in respect of the proposed merger transaction involving SIGA Technologies, Inc. and PharmAthene, Inc. In addition, SIGA has filed a preliminary proxy statement with the SEC in connection with the transaction and will mail the definitive proxy statement to SIGA shareholders of record at the record date for the special meeting of the shareholders to be held to provide approvals relating to the proposed transaction. The definitive proxy statement that SIGA plans to file with the SEC and mail to its shareholders will contain information about SIGA, PharmAthene, the proposed merger, and related matters. SHAREHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT CAREFULLY WHEN IT IS AVAILABLE, AS IT WILL CONTAIN IMPORTANT INFORMATION THAT SHAREHOLDERS SHOULD CONSIDER BEFORE MAKING A DECISION ABOUT THE MERGER. In addition to receiving the proxy statement and proxy card by mail, shareholders will also be able to obtain the definitive proxy statement, as well as other filings containing information about SIGA, without charge, from the SEC's website (http:/www.sec.gov) or, without charge, by contacting Thomas Konatich at SIGA at (212) 672-9100. This announcement is neither a solicitation of proxy, an offer to purchase, nor a solicitation of an offer to sell shares of SIGA.
SIGA and its executive officers and directors may be deemed to be participants in the solicitation of proxies from SIGA's shareholders with respect to the matters relating to the proposed merger. PharmAthene may also be deemed a participant in such solicitation. Information regarding SIGA's executive officers and directors is available in SIGA's Annual Report on Form 10-K, for the year ended December 31, 2005. Information regarding any interest that PharmAthene or any of the executive officers or directors of PharmAthene may have in the transaction with SIGA will be set forth in the definitive proxy statement that SIGA intends to file with the SEC in connection with the matters to be approved in connection with the proposed merger. Shareholders of SIGA can obtain this information by reading the definitive proxy statement when it becomes available.
Posted by matto on :
wow, wish I was in this before the nes was released
Posted by Leslie C on :
Aftermarket Mover: PMC Slides on Warning Monday September 25, 5:29 pm ET PMC Sierra Shares Fall After Sales Shortfall Warning; AngioDynamics Shares Climb After Strong 1Q Results
NEW YORK (AP) -- Telecom and networking semiconductor company PMC-Sierra Inc. saw its shares recede in after-hours electronic trading Monday after it warned of lower than expected revenue for the third quarter.
ADVERTISEMENT click here PMC said it expects sales for the quarter to range from $114 million to $116 million, down from the second quarter and below the company's previous outlook of $122 million to $124 million.
Analysts, on average, were looking for sales of $123.2 million, according to a poll by Thomson Financial.
The company said demand was lower for its communications products, and added that, thanks to cost-cutting measures, it also expects its operating expenses to be lower than its prior forecast.
The Santa Clara, Calif.-based company's shares fell 68 cents, or nearly 10.4 percent, to $5.87 in after-hours trading on the INET electronic exchange. The stock closed up 8 cents at $6.55 on the Nasdaq.
Vaccine developer Siga Technologies Inc., meanwhile, saw its stock nearly double after privately held PharmAthene Inc., which is in the process of acquiring a majority stake in Siga, received a large Department of Defense contract.
PharmAthene, of Annapolis, Md., said it received a multiyear contract worth up to $213 million for the development of Protexia, a "pre- and post-exposure therapy for casualties on the battlefield or civilian victims of nerve agent attacks," as described on the company's Web site.
New York-based Siga's shares rose 93 cents, or 88 percent, to $1.99 in after-hours trading, having closed up a penny at $1.06 on the Nasdaq.
Shares of medical device maker AngioDynamics Inc. also climbed, after the company said its fiscal first-quarter profit jumped 47 percent as sales of its drainage catheters and other products climbed.
The results beat analyst expectations, and the Queensbury, N.Y. company's shares rose 90 cents, or 4.7 percent, to $20.15 on INET, after closing up 60 cents, or 3.2 percent, at $19.25 in the regular trading session on the Nasdaq.
Also on the medical front, Arena Pharmaceuticals Inc.'s shares slid 86 cents, or 7 percent, to $11.39 on INET after the drug developer said its development partner Merck & Co. Inc. stopped work on a potential atherosclerosis treatment, citing results from a mid-stage study.
San Diego-based Arena's shares closed up 3 cents at $12.25 in the regular trading session on the Nasdaq.
Merck shares dipped a penny to $41.95 on INET, from their New York Stock Exchange close at $41.96.
Posted by Repoman75 on :
Damn, missed this one
Posted by Dave2007 on :
wow, up over 84% in after hour trading ::bangs head::
Posted by cpeed on :
Im sure it will run huge tommorrow.
Posted by Repoman75 on :
Hit $2.10... need more info. on the company
Posted by Repoman75 on :
I'm in $2.20. Next FRPT maybe.
Posted by Repoman75 on :
From a poster on SI:
So sweet. I had also just bought another 5K shares last week *$1.03. If SIGA owns 32.5% of PharmAcene that would be like them getting a 65M grant. Keep in mind that PharmAcene has several other big bio-defense drugs in their pipeline. Their drug Valartim is supposed to be their flagship moneymaker. Those of us who own SIGA know they also have potential blockbusters including SIGA 246 which is the most advanced smallpox vaccine, and get this ...it is oral - no shots. How much would that be worth if it was ordered worldwide? I said months ago that I would not think about selling until at least $7. I think that might now be too low. Baton
Posted by cpeed on :
I jumped in this morning
Posted by Fuzzy1018 on :
This was a big news yesterday; missed the intial run but in now at 2.04- i think this will run to much higher levels
Posted by Jo4321 on :
Took advantage of the lunchtime dip and got in at $1.90.
So you think this coudl be the next FRPT, Repo? That'd be sweet!
Jo
Posted by Fuzzy1018 on :
I should've waited a little longer, but oh well I'm preety satisfied with my entry bcuz this will go again
Posted by Repoman75 on :
Well, its a huge contract, they are beginning to make revenue, and insiders loaded up in the 1.60's. I like its prospects. Have to do more DD but I'm in for now.
Posted by Fuzzy1018 on :
heading back up now
Posted by Fuzzy1018 on :
whats goin' on here
Posted by Fuzzy1018 on :
i hate bid whackers
Posted by Jo4321 on :
Just getting primed for an EOD run.
Posted by Fuzzy1018 on :
Looking forward to an EOD run here, lets see what hppns
Posted by Repoman75 on :
Patience! Stop wishing for 100% gainers in 1 day.
Posted by Jo4321 on :
Okay. How 'bout tommorrow then? Posted by ABEX TRADER on :
WOW! This has a very small float!27.5 Mil with 5Mil traded yesterday before AH's!
Posted by Dave2007 on :
quote:Originally posted by Repoman75: Patience! Stop wishing for 100% gainers in 1 day.
so does this mean a 300% gainer in two days is out of the question? Posted by TheRisktAkEr on :
I'm a newbie, invested some money in this one yesterday without much research on the company. Any thoughts would be appreciated and helpful. It's not looking too good right now
Posted by TheRisktAkEr on :
it actually took a nice dip and now its moving up fast
Posted by TheRisktAkEr on :
anyone in this?
Posted by Repoman75 on :
I'm in.
Posted by TheRisktAkEr on :
well repoman, reading ur posts above it seems as if u really like this stock. Next FRPT - that would be great; I think patience is the key to win with this particular stock
Posted by ABEX TRADER on :
Does this have more downside to come?
It might swing low and then gather up the lower price then run I think.
It could also spike up again.It needed to retrace to allow the MA's to catch up.
I bought some also,but did not fill the whole position I will take.
Posted by Repoman75 on :
Yeah, I bought more at 1.55, averaged down. But I'm just going to hold for awhile. Have to wait until financials when this contract hits the bottom line. Just be patient.
Posted by glassman on :
quote:Originally posted by Repoman75: Yeah, I bought more at 1.55, averaged down. But I'm just going to hold for awhile. Have to wait until financials when this contract hits the bottom line. Just be patient.
amazing repo...
did you read the Filing Date: 9/19/2006 Form Type: PRER14A
Repo...would this fall under your rule #3 or #5? J/K...
quote:Originally posted by Repoman75: Yeah, I bought more at 1.55, averaged down. But I'm just going to hold for awhile. Have to wait until financials when this contract hits the bottom line. Just be patient.
Posted by Repoman75 on :
Yeah I saw that filing. Did you see what amount of this contract? This stock WAS a dog, but not now. Everyone has to start somewhere.
Let's see how 2 months goes vs. 2 days, mmkay?
Posted by glassman on :
that's a lot of shares man..
this is why it's so hard to make money in the pennies...
if the shares are not even out of the co treasury yet, but somebody is already selling them???
write a letter to your congressperson or Senator,
that's all i ask...
'nuff said... peace man...
Posted by Dave2007 on :
Repoman... at this point would you recomend buying on this stock still?
Posted by Repoman75 on :
I'm gonna hold.. if its 1.30, I'm out.
Posted by Fuzzy1018 on :
gappin' up
Posted by Dave2007 on :
not much activity on this today, down .05 so far =\
Posted by Jo4321 on :
Well, it never did go down to $1.30, Repo. You still in this? Anyone else still monitoring it?
Least we have a little upward movement today.
Jo
Posted by Repoman75 on :
In it... just holding for now.
Posted by Jo4321 on :
Not a bad close, up nearly 13%
I made a rash decision when I bought this, hope it doesn't come back to haunt me.
Jo
Posted by Dave2007 on :
you and me both... but i think it will slowly go back up with time.
Posted by Repoman75 on :
1.90 now. I told you, PATIENCE.
Posted by Repoman75 on :
$2 now.
Posted by Lootcifer on :
Press Release Source: SIGA Technologies, Inc.
SIGA Receives $16.5 Million from the NIH to Advance Development of Its Smallpox Drug Candidate, SIGA-246 Wednesday October 4, 5:05 pm ET Total Funding Awards Received by SIGA since August 2, 2006 Now Exceeds $27 Million
NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) today announced the receipt of a 3 year, $16.5 million contract from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes for Health (NIH), to advance the development of SIGA-246, the company's smallpox drug candidate. The award will support the development of SIGA-246 through the preparation and filing of a New Drug Application with the Food and Drug Administration. The receipt of this award brings the total amount of funding commitments the company has received from various sources since August 2nd to over $27 million.
ADVERTISEMENT "We are grateful for the continued commitment of the NIH to the development of SIGA-246," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. "The funding we have received from the NIH, as well as their advice and guidance have been critical to the success of our smallpox drug program to date. We look forward to continue working with the NIH as SIGA-246 advances forward."
In July 2006, SIGA announced the successful completion of its first human clinical safety trial. The preliminary results indicated that SIGA-246 is safe and well tolerated in human volunteers at all tested orally administered doses.
SIGA believes that SIGA-246 is the most advanced smallpox treatment currently in development. It represents a new approach to achieve a novel, orally active, antiviral therapeutic to smallpox. The Centers for Disease Control and Prevention classified smallpox as a Category A agent. It is considered one of the most significant threats for use as a bio-warfare agent due the fact that people in the United States have not been vaccinated against it since 1972. Smallpox is very easily transmitted from person to person, and has high mortality rates (30-60%) with 90% morbidity. At present there is no approved treatment for smallpox that can be safely administered to the general population without significant risk of adverse reactions. "We are committed to continue the development of SIGA-246 and hope to provide a solution to this urgent bio-security need," commented Dr. Hruby.
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA has the potential to become a significant force in the discovery of vaccine and pharmaceutical agents to fight emerging pathogens. SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria. In addition to smallpox, SIGA has antiviral programs targeting other Category A viral pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).
For more information about SIGA, please visit SIGA's Web site at www.siga.com.
Forward-looking statements
This Press Release contains certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, and (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release and the above-mentioned presentation, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.
Contact:
SIGA Technologies, Inc. Thomas N. Konatich, 212-672-9100
Source: SIGA Technologies, Inc.
Posted by Lootcifer on :
AP Siga Pulls Out of PharmAthene Merger Wednesday October 4, 5:43 pm ET Siga Pharmaceuticals Ends Proposed Merger With PharmAthene, Cites $27 Million in Grants
NEW YORK (AP) -- Siga Pharmaceuticals Inc., which develops vaccines, said Wednesday it ended a proposed merger with PharmAthene Inc., a private biotechnology company, nudging up shares after the market closed.
Siga said a number of factors affect its decision, including a $16.5 million grant from the National Institutes of Health for development of the company's smallpox drug candidate, Siga-246, also announced Wednesday.
The NIH grant brought the company's total grant funding since Aug. 2 to more than $27 million.
The two companies first said they would merge and operate under the PharmAthene name in March, but did not disclose financial terms of the deal.
Shares of Siga gained 7 cents at $1.83 in after-hours trading on the INET electronic exchange.
Posted by AshyToClassy on :
Been looking for a buying opportunity all day, and I think I just found it here in SIGA.
Posted by AshyToClassy on :
Two PRs after hours just five minutes apart. Lets decipher them. First PR is great mentioning that they have a lot more grant money from the government, which means they no longer have to depend on PharmAthene fas a middle man to the government contracts and money. Thats a good thing. Most cancelled mergers are usually bad for a company but not in this case.
The Chairman of the Board hinted at something big in the second PR which I believe will move the PPS upwards tomorrow going into Friday. He said:
The main reasons for calling off the merger was due to "recent positive scientific data and the receipt of approximately $27 million in grants for its smallpox and arenavirus programs over the last several months".
The way I see it, it sounds like they have more contarcts in the works with significantly more funding behind them. That recent positive data from their clinical trials also hints that they will be PR'ing some big findings for the phase two clinical trial. Remember phase 1 was a complete success and it sound like phase 2 trial will follow the same path leading up to the pivotal phase 3 trials that the FDA panel focuses on.
Posted by Lootcifer on :
I made a great call on ACOR over the weekend and I'm gonna do the same here. After combing thru both press releases. I went back and reviewed the stock movement in after hours. All in all the funding PR pushed the PPS up to an initial high of $2.05, a 24% increase after market close.
The end of merger PR pulled it back to 7% lower than the end of day closing PPS of $1.78. It hit a low of $1.50 which ushered in a quick buying pressure that raised the volume from 993,000 shares to 1,023,000 shares. Investors saw the buying op and scooped up some cheap shares. The end of merger PR was a positive release in itself. Howe? Because It states the company was now going self sufficient, had this new money backing them, and more positive trial data to increase chances of FDA approval. I won't be surprise at all to see an early pre-market PR detailing this further. IMO, I see this trading between the 1.80 and 2.15 range tomorrow. But this is just my opinion.
The scared hands sold of in after hours to protect capital. WHo had time to compare two PR's 5 minutes apart while the PPS was heading down. They had to protect their capital. But looking through both releases shows that the SIGA is heading in a much positive direction than you'd think initially. The stock had great support in the $1.60 range and it sounds crazy but I see this gapping up bigtime in the morning.
Posted by Lootcifer on :
I wish I could find out more details about that recent positive data the BOD guy is talking about. Boy I envy those with insider info. If only I could be invisible in their boardroom.
Posted by AshyToClassy on :
quote:Originally posted by Lootcifer: I wish I could find out more details about that recent positive data the BOD guy is talking about. Boy I envy those with insider info. If only I could be invisible in their boardroom.
All in favor say Aye!!! I second the motion. But we all gotta wait til tomorrow. BTW I dropped the company an email just for the hell of it asking if they had a followup PR for tomorrow or Friday. Thought I'd give it a shot, it never hurts to try my friends after all its your money.
Posted by Lootcifer on :
Good morning everyone. Lets see how SIGA pans out today. We had a late selloff yesterday from those that were holding and then the buying pressure started on the dip. They're on their own now with their own money which seems to be sufficient according to the Chairman. They wouldn't have ended the merger if they were'nt confident that they can survive without an alliance. I'm watching this very closely today. IMO this will be a very big play for whoever is just coming in. Those that had bought much higher sold for a loss and fresh hands bought in at the very low which started bringing the PPS back up.
Posted by Hustla on :
quote:Originally posted by Lootcifer: Good morning everyone. Lets see how SIGA pans out today. We had a late selloff yesterday from those that were holding and then the buying pressure started on the dip. They're on their own now with their own money which seems to be sufficient according to the Chairman. They wouldn't have ended the merger if they were'nt confident that they can survive without an alliance. I'm watching this very closely today. IMO this will be a very big play for whoever is just coming in. Those that had bought much higher sold for a loss and fresh hands bought in at the very low which started bringing the PPS back up.
Morning stock heads. Hey loot I remember all the DD you did and the predictions you made this past weekend and it did exactly what you said. That thing pulled back to $9.10 then shot up sky high to $12.50 by Tuesday afternoon. Good call man. I made serious cash there. So you seet this happening with SIGA too huh?
Posted by Lootcifer on :
I indeed think so hustla. It seems the biotechs are red hot right now, thanks in part to the crazy push from ACOR successful phase 3 clinical trials. Man no one saw that thing shooting from $2.22 to $12.50 in one week and a couple days.
Posted by Lootcifer on :
The Momentum came back in the stock and between today and maybe middle of next week, this should be trading between $2.00 and $2.50 if not $3. IMO
Posted by Lootcifer on :
There's on thing to note today intrading the stock. If you wanna get in early the MMs are gonna make you chase it. They really don't like giving out cheap shares. The game is to make you buy high and sell low, which tons of people did yesterday after the first PR came out about the new funding the company got to finance the smallpox drug. MMs are tricky they are in it for themselves and whichever firm or individual they represent. Wouldn't wanna be one but sometimes I envy there power in the market. Play with them not against them and you just might come out with a small profit, LOL Posted by Hustla on :
For a minute I was gonna say $3 was a little bit too high of a prediction but, then again the stock hit over $2 in early after hours yesterday. I won't argue with your prediction, but I like to give props to posters when I see their words come true. Well you were on point with your ACOR prediction. This isn't a micropenny either so the rules and trading trends are different on the Nasdaq.
Posted by Hustla on :
Well pre-market trading is over for regular investors. 9:30 to 4pm will tell the story for the stock today. I'm looking for a good flip today. Perhaps this might be it.
Posted by Hustla on :
Looking at the level 2, MMs always create such huge spreads to make more money on their trades.
Right now Bid at $1.56 and Ask at 1.68. I'm sure that will change at opening bell though.
Posted by Lootcifer on :
For whoever is currently in this there's no need to worry, its down right now, but it will rebound as the day progresses. If you're looking to flip, look for any good dips. The charts will help you out on this one.
Posted by Hustla on :
This thing is poised to fly today when the CEO or chairman release the followup PR explaining more about the updates on the SIGA-246 smallpox drug. And I say when because the Company head indicated in yesterdays PR that they have positive new data.
They tend to release PRs middle of day and after hours. Watch the newswires for something.
Posted by Lootcifer on :
Look at MAXM sittin at the bottom of the Ask at $4.00 Hehe
Posted by Repoman75 on :
You 2 are really pumping this eh?
Posted by Hustla on :
quote:Originally posted by Repoman75: You 2 are really pumping this eh?
Why not there's a huge dip here and I'm lookin to flip. I'm not holding anything that ain't my game Repo. I assume you're already out??
Posted by Lootcifer on :
I curious to know Repo, whats your take on the stock right now?
Posted by Repoman75 on :
I'm sold in the 1.80's for a short gain yesterday, but I'm looking to reload.
Posted by Hustla on :
If this thing really does have the potential to reach $3 or more soon, I'm flippin all the way. ACOR paid me well so far this week, and I'm eyeing this as my next pay day.
I'll say this much, MMs shook the hell out of a lotta people this morning.
Posted by wadeinni on :
Whoever is in charge of press releases over there should have released the cancelled merger PR only yesterday, and release the new funding PR this morning. It would have definitely have a more upwards effect on the PPS. They better release something else to fix the mistake. As you can see people got scared and left rewarding the MMs with cheap shares galore.
Posted by Hustla on :
quote:Originally posted by wadeinni: Whoever is in charge of press releases over there should have released the cancelled merger PR only yesterday, and release the new funding PR this morning. It would have definitely have a more upwards effect on the PPS. They better release something else to fix the mistake. As you can see people got scared and left rewarding the MMs with cheap shares galore.
What can I say, yesterdays investors lost is my gain today. What can I say. This is a great chance to flip today and I'm only capitalizing on it.
Posted by Lootcifer on :
I have some good news for anyone who've been holding SIGA since the termination of the merger. It appears one of their options if the merger had gone through was to implement a reverse stock split to satisfy Nasdaq listing requirements.
Thats is NO LONGER the case. I called investor relations number (212-672-9100)in New York City about 10:40 am this morning and spoke to a guy name Bob.
He confirmed to me that SIGA WILL NOT do a reverse stock split since they now have enough funding to support their research in the clinical trial phases. You can call them yourself at the number listed above. Its directly listed on their website h t t p : / / w w w . s i g a . c o m and the secretary puts you through to the investor relations guy quickly.
Posted by Repoman75 on :
1.84 again.
Posted by Lootcifer on :
One thing I did forget to mention regarding the previous phone call to investor relations on Friday was that, between now and the end of the month the company will aggressively seek to increase the value of the company thru more contracts with the government and maintain a PPS above $4 per share.
Reasons being they're aiming to get FDA approval for SIGA-246 Smallpox drug and keep good standing on the Nasdaq Bulletin Board at the same.
Posted by wadeinni on :
I was able to get in on Friday at $1.67 and sold by late afternoon at $1.88. Whats interesting to me about Thursday and Friday's trading was how the PPS traded down as low as 19% on Thursday then reversed and traded up 20% on Friday in late afternoon. Somehow it looked like the MMs did it purposefully to load up for the run we saw in the afternoon.
I did get a sigh of relief to hear that the company was answering investors questions with positive news regarding the stock price and direction. No R/S is always a good thing for the little guys.
Posted by Lootcifer on :
quote:Originally posted by Repoman75: 1.84 again.
Hey Repo, I know you sold at 1.80, but did you get back in on any of the dips for another flip??? BTW, you're the one that brought my attention to this stock right before they had released the back to back PRs on Wednesday. Thanks for the heads up with your previous postings. I made some good cash on this stock. Just a week ago it wasn't even on my radar.
Posted by Hustla on :
There's pretty much 5 Nasdaq stocks I have on my radar for the past two weeks that are guaranteed for 10 to 15 percent flips. I don't play the micro-pennies anymore because they are way too manipulated, like MMs tanking a stock on great financial data, and naked shorting all over the place. I don't hold any of them, becuase I'm a practicing flipper.
They are SIGA, ACOR, GNTA, VSGN, and CORT.
I would flip CSHD on the OTCBB Board but I use Ameritrade and they have that buy restriction. A'holes!!! Just opened Scottrade account and will use them starting next week. I watch SIGA and ACOR especially because they're on a nice uptrend right now.
Posted by Lootcifer on :
CSHD holding up very well today. Lets see if we can break 2$ by EOD. Taht would be nice
Posted by Repoman75 on :
CSHD is crap. This however, is a long term play.
Posted by AshyToClassy on :
quote:Originally posted by Repoman75: CSHD is crap. This however, is a long term play.
Hey Loot I agree with Repo on this one. CSHD is in the chithole now even with the promised 10K and price reset. Your calls however on ACOR and SIGA have been pretty good. Posted by Jo4321 on :
since you're talking about both of them, it is a coincidence that CSHD and SIGA are the exact same PPS right now: $1.88
Which one will end up higher today?
Jo
Posted by Lootcifer on :
Holy crap she just took off to the moon, and I'm riding well!!!!!!!!!!!!!
Press Release Source: SIGA Technologies, Inc.
SIGA Announces Smallpox Treatment Breakthrough Wednesday October 18, 7:30 am ET SIGA Drug Completely Prevents Smallpox Disease in Preliminary Primate Trial
NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today that its lead drug, SIGA-246, is the first drug ever to demonstrate 100% protection against human smallpox virus in a primate trial conducted at the federal Centers for Disease Control and Prevention (CDC). In this study, once-daily, oral administration of SIGA-246 protected cynomolgus monkeys from smallpox disease following intravenous high dosing with smallpox virus. The drug prevented symptoms of disease whether delivered at the same time as the virus or 24 hours later, supporting the drug's use for both post-exposure prophylaxis and treatment. SIGA-246 completely prevented lesion formation and reduced viral load to non-threatening levels in treated animals with no obvious toxicity. The study was conducted under rigorous bio-safety and -security conditions at the World Health Organization Collaborating Centers for Smallpox and Other Poxvirus Infections' BSL-4 laboratory located at the CDC in Atlanta and was funded by the Department of Health and Human Services, the CDC and the Department of Defense's Defense Threat Reduction Agency under the supervision of Dr. John Huggins, Chief of the Viral Therapeutics Branch, U.S. Army Medical Research Institute of Infectious Diseases.
ADVERTISEMENT click here Dr. Huggins commented, "This drug holds great promise as a therapy for poxvirus infections." Donald Drapkin, Chairman of SIGA, added, "Smallpox is one of the great biowarfare threats, and SIGA-246 demonstrates SIGA's leadership in efforts to counteract that threat."
"We are particularly pleased," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA, "because the amount of virus used in this study is equivalent to the level present in late-stage disease in humans, which we believe signals that SIGA-246 can be used to prevent disease in humans even several days after initial viral exposure." He added, "This test in non-human primates is as close as anyone can get to the real thing because there has not been any natural occurrence of smallpox since 1977."
Smallpox is considered one of the most significant biowarfare threats. The CDC classifies variola, the virus that causes smallpox, as a "Category A" (highest level threat) bioterrorism agent. Smallpox is readily transmitted between humans, it has significant mortality rates and the population is no longer vaccinated against it. Mass immunizations of the general population using the current live vaccine are not recommended, as there are known complications affecting some individuals, which may include encephalitis, myocarditis, and death. Immunocompromised individuals receiving this vaccine are at particular risk from a systemic infection. At this time, there is also no approved treatment for smallpox.
The Department of Homeland Security has designated smallpox a "material threat" to our national security, so SIGA-246 will be eligible for purchase for the Strategic National Stockpile under Project Bioshield.
SIGA previously announced that SIGA-246 has been shown to be safe to administer to humans as a once-a-day pill. SIGA-246 has also demonstrated 100% disease protection in several mouse models of infection, which results SIGA will use, along with additional tests yet to be completed, to fulfill the U.S. Food and Drug Administration's "Animal Efficacy Rule." In December 2005, the FDA granted "fast-track" status to SIGA-246.
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). SIGA's product development programs also emphasize the increasingly serious problem of drug resistant bacteria.
For more information about SIGA, please visit SIGA's Web site at www.siga.com.
About the Defense Threat Reduction Agency
The Defense Threat Reduction Agency (DTRA) is an agency of the U.S. Department of Defense that safeguards America and its allies from weapons of mass destruction by providing capabilities to reduce, eliminate, and counter the threat, and mitigate its effects. DTRA headquarters is located at Fort Belvoir, Virginia, and it also operates field offices worldwide. The DTRA has identified an orthopox therapeutic as a critical need in its ongoing threat reduction efforts.
About the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a critical role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Material Command.
The information contained in this press release does not necessarily reflect the position or policy of the U.S. government, and no official endorsement should be inferred.
Forward-looking Statements
This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.
Contact:
Rubenstein Associates, Inc. Debbie Raskin, 212-843-8028 draskin*rubenstein.com
Posted by Repoman75 on :
Wow, can I pick them or what??? Too bad I sold early... trading in the 4's now!
Posted by Lootcifer on :
Up 128% in pre-market!!!!!!!!!!!!!!!!!!
Posted by Lootcifer on :
Lets see if this goes anywhere near where ACOR went in one week. I'm watching for a pullback, I wanna purchase some more.
Hey Repo you gonna try for this or GTF today??
Posted by Repoman75 on :
I'm getting in GTF for a nice bounce... this, I don't know... it won't open in the 5's, probably low 4's or even high 3's... see what happens.
Definitely wait for a dip.
Posted by Lootcifer on :
Yeah I agree, buy 9am there should be major profit taking. I do see a high 3's opening. I expected this news but not this early.
Posted by Repoman75 on :
I knew this was a long term winner... Gov't doesn't give contracts to losers. Next FRPT.
Posted by Repoman75 on :
$6.50 now... damn my exit strategy stunk on this one.
Posted by Lootcifer on :
I wanted more shares but I thought an 85% opener was too high. Looks like I'm kicking myself in the a$$ hard right now. Wow Posted by Lootcifer on :
This is nuts. over 3 million shares traded already. Thats 12 times its average daily volume. I'm rethinking, the real pullback might not even come until after the market opens.
Posted by Repoman75 on :
Yeah, pullback on this AH trading ALWAYS comes... right its like the Wild West. Traders picking off orders and slinging shares.
Posted by BooDog on :
congrats here! FAR OUT!
Posted by Lootcifer on :
quote:Originally posted by BooDog: congrats here! FAR OUT!
Thanks BooDog. I was already in but not that many shares. I have another 5K I wanna drop on this but I'm looking for the right entry point. Its waaaaay to high right now to get in.
Posted by Repoman75 on :
$5 is holding... wow, this may hit $8 today.
Posted by Repoman75 on :
You just had your dip at $4.90.. watch it fly now.
Posted by Lootcifer on :
Damn I missed the dip, had to go drop my kids off at preschool. Still watching though. If I don't get in, I won't complain. I'm not the greedy type.
Posted by SherriT on :
Congrats everyone - was waiting to put some CSHD $ here, but it took off before I was ready....awesome pick you guys!
Posted by Lootcifer on :
quote:Originally posted by SherriT: Congrats everyone - was waiting to put some CSHD $ here, but it took off before I was ready....awesome pick you guys!
thanks Sherri, still waiting for the dip again though to get some more. Oh well, kids come first.
Posted by Jo4321 on :
You guys aren't going to believe this. I had a GTC order in yesterday for $2.00 that took.
My reverse Midas touch strikes again.
Jo (sneaking in on the school computer)
Posted by Livinonklendathu on :
CEO is on CNBC
Posted by dollar13 on :
very nice pick GUYS
CONGRAT............
Posted by dollar13 on :
hugeeeeeeeeeeeeeee VOLUME Damnnnnnnn
Posted by SherriT on :
quote:Originally posted by Jo4321: You guys aren't going to believe this. I had a GTC order in yesterday for $2.00 that took.
My reverse Midas touch strikes again.
Jo (sneaking in on the school computer)
Jo, you are just fighting a losing battle with yourself, aren't you? Sorry to hear that...hopefully Sabra and Rufie will come through for you with some shares!
Posted by Lootcifer on :
You know I just remembered that they are awaiting FDA approval for this same smallpox drug?
If there was any dougbt before of whether they will get it, I think this news just made it a done deal. Holy crap, I wonder if this will be a multiday runner like ACOR??
Between now and Monday will tell. But one things for sure the momentum in this is far from over.
Posted by wadeinni on :
There's 4 really big things that are about to make this company explode even more than it did today.
1. FDA approval is imminent
2. A substantial increase in funding from the US government.
3. There's more than likely going to be an analyst upgrade.
4. The stock price is definitely gonna increase from here on.
If you're a daytrader, today was great for you. If you're a swing trader between today and next week is gonna make your portfolio so fat and green.
Everyone keeps mentioning them, but ACOR is the poster child of biotech stocks for this type of movement.
The average stock won't even get one out of the four listed above. Too bad I had gotten out when it hit 1.97.
Posted by Lootcifer on :
What completely blew me away in pre-market trading was how easily it went over $6. I didn't buy it because it opened at 3.75 from a previous close of $1.97. That was an 85% opening. There's no way I was gonna buy it so high but then I saw it rocketed to 230% ($6 something) by 9am and I felt like such a jacka$$.
I could have made sooo much more money today. Hell I coulda made close to a double on $5K.
Posted by wadeinni on :
quote:Originally posted by Lootcifer: What completely blew me away in pre-market trading was how easily it went over $6. I didn't buy it because it opened at 3.75 from a previous close of $1.97. That was an 85% opening. There's no way I was gonna buy it so high but then I saw it rocketed to 230% ($6 something) by 9am and I felt like such a jacka$$.
I could have made sooo much more money today. Hell I coulda made close to a double on $5K.
WHAT!!!!!!!? No way
This hit $6 this morning?? Ch1t, thats what I get for selling so hastily, plus waking up late this morning. That would have been over a 300% gain for me today. Now I feel like Jo4321 that sold too early.
Posted by Lootcifer on :
quote:Originally posted by wadeinni:
quote:Originally posted by Lootcifer: What completely blew me away in pre-market trading was how easily it went over $6. I didn't buy it because it opened at 3.75 from a previous close of $1.97. That was an 85% opening. There's no way I was gonna buy it so high but then I saw it rocketed to 230% ($6 something) by 9am and I felt like such a jacka$$.
I could have made sooo much more money today. Hell I coulda made close to a double on $5K.
WHAT!!!!!!!? No way
This hit $6 this morning?? Ch1t, thats what I get for selling so hastily, plus waking up late this morning. That would have been over a 300% gain for me today. Now I feel like Jo4321 that sold too early.
Yeah thats right. I was watching it and commenting with Repo as it rocketed. Within the first hour alone, volume had skyrocketed to over 3 million shares. That was 12 times the average daily. Now look at it.
Its at 36 million shares now. Thats 159 times the average daily volume. What does that tell you about this stock between tomorrow and the coming days. Look for a flood of PRs IMO.
Posted by Jo4321 on :
quote:Jo, you are just fighting a losing battle with yourself, aren't you? Sorry to hear that...!
Yeah, I'm thinking of starting a thread where I tell you folks when I sell something, so you all can get in
I'm also watching ACTC which I sold last week at .65 now going up to .83
Of course, the ones I hold go down (PBLS, RKLC)
I almost wasn't going to post here that I sold SIGA yesterday cause I didn't think anyone would believe someone could be such a bad trader. But sadly, it is true. I did make 60 bucks or so on it! (vice $3500 if I would have sold at $5.50). Guess I'll just say that a little profit is better than none, and move on.
Definitely won't mention this one to hubby.
Jo
Posted by wadeinni on :
quote:Originally posted by Jo4321:
quote:Jo, you are just fighting a losing battle with yourself, aren't you? Sorry to hear that...!
Yeah, I'm thinking of starting a thread where I tell you folks when I sell something, so you all can get in
I'm also watching ACTC which I sold last week at .65 now going up to .83
Of course, the ones I hold go down (PBLS, RKLC)
I almost wasn't going to post here that I sold SIGA yesterday cause I didn't think anyone would believe someone could be such a bad trader. But sadly, it is true. I did make 60 bucks or so on it! (vice $3500 if I would have sold at $5.50). Guess I'll just say that a little profit is better than none, and move on.
Definitely won't mention this one to hubby.
Jo
Don't feel bad Jo, I did the same thing. You made a decision and stuck by it. Warren Buffet says a profit is a profit. Its better you made 60 bucks than lost 500. Posted by wadeinni on :
Whats gonna suck is watching it go even higher like ACOR and I'll just have to sit back and shake my head in amazement and wonder what coulda happened to my portfolio.
I tell you one thing, a lot of my bills would have gotten paid nicely this week. Posted by Jo4321 on :
Thing is, I can still afford to buy a bit at these prices (not nearly what I could afford when I bought at 1.90), so I'm tempted to buy in.
Jo
Posted by wadeinni on :
I sold 75% of my CSHD holdings at 3.90 and never looked back. I saw that you sold day before yesterday Jo. I don't blame you on that one either. The way Rufus put out the 10K and other news was just too messy. Honestly I have no more confidence in CSHD. Just riding the other 25% of my free shares to see what happens.
But anyway this is SIGA let me stick to the subject Posted by Lootcifer on :
I know I shouldn't do this, but based on the possibilities of the next few days. I think this will see $8. The volatility speaks for itself right now. Posted by Lootcifer on :
Hey Repo you out there?
Did you get back in??
Posted by Jo4321 on :
I know this is off topic, but I here's someone with worse luck than me.
--------------------------
U.S. casino magnate gives Picasso's dream the elbow Wed Oct 18, 9:43 AM ET
LOS ANGELES (Reuters) - Picasso's famed "Dream" painting turned into a nightmare for Las Vegas casino magnate Steve Wynn when he accidentally gave the multimillion dollar canvas an elbow.
Wynn had just finalized a $139 million sale to another collector of his painting, called "Le Reve" (The Dream), when he poked a finger-sized hole in the artwork while showing it to friends at his Las Vegas office a couple of weeks ago.
Director and screenwriter Nora Ephron, who witnessed and related the incident in her **** on the Huffington Post Web site (www.huffingtonpost.com), said Wynn had raised his hand to show the group something about Picasso's 1932 portrait of his mistress Marie-Therese Walter.
"At that moment, his elbow crashed backward right through the canvas. There was a terrible noise," Ephron wrote, noting that Wynn has retinitis pigmentosa, an eye disease that damages peripheral vision.
"Smack in the middle ... was a black hole the size of a silver dollar. 'Oh s---,' he said. 'Look what I've done. Thank goodness it was me.'"
Wynn's office on Tuesday confirmed the story, an account of which also appeared in this week's The New Yorker. Both accounts said Wynn had decided to release the buyer from the sale agreement and to repair and keep the painting himself.
Wynn, a millionaire casino developer and art collector, developed The Mirage and Bellagio resorts in Las Vegas in the 1990s, which spearheaded a profusion of luxury hotels and casinos on the once-seedy Las Vegas Strip.
Posted by Lootcifer on :
Wow, I wouldn't wanna be that guy right now. He better have a brass pair, cause thats gotta hurt. Can you imagine the amount of money he lost with that elbow to the painting?? Posted by wadeinni on :
I can't keep up with the level 2 on this thing its moving so fast.
Posted by SherriT on :
quote:Originally posted by wadeinni:
quote:Originally posted by Jo4321:
quote:Jo, you are just fighting a losing battle with yourself, aren't you? Sorry to hear that...!
Yeah, I'm thinking of starting a thread where I tell you folks when I sell something, so you all can get in
I'm also watching ACTC which I sold last week at .65 now going up to .83
Of course, the ones I hold go down (PBLS, RKLC)
I almost wasn't going to post here that I sold SIGA yesterday cause I didn't think anyone would believe someone could be such a bad trader. But sadly, it is true. I did make 60 bucks or so on it! (vice $3500 if I would have sold at $5.50). Guess I'll just say that a little profit is better than none, and move on.
Definitely won't mention this one to hubby.
Jo
Don't feel bad Jo, I did the same thing. You made a decision and stuck by it. Warren Buffet says a profit is a profit. Its better you made 60 bucks than lost 500.
Agreed. I've heard "shoulda coulda woulda" a lot. If you just make safe trades for $60 a day, you won't care about the ones you missed in a while....
Posted by Dave2007 on :
whew, I was getting worried because I had bought in on this stock awhile ago * 2.20. =)
Posted by Stockstar69 on :
Another day! Wonder what today will bring? Will we go back down to where we were last week or are we running now with the big news?
Anyone see any chance of a buyout by another big pharma?
Posted by Lootcifer on :
quote:Originally posted by Stockstar69: Another day! Wonder what today will bring? Will we go back down to where we were last week or are we running now with the big news?
Anyone see any chance of a buyout by another big pharma?
I don't see that happening. In their previous PR they ended the merger with PharmaThene because they claim to have enough funding to sustain themselves. And obviously they had these results for smallpox but just wasn't ready to drop the news til yesterday.
I expect them to get an enormous amount of extra funding from other sources. JMO
Posted by Repoman75 on :
Have to wait for a retrace in a few days.. maybe jump in.
Posted by Repoman75 on :
News out, PP of stock at 4.54. THat's your support. Institutions will be on the way down. THis will hit $7 very soon.
Posted by invester on :
Just picked up 1000 at $4.29 pre market.
Posted by Lootcifer on :
quote:Originally posted by invester: Just picked up 1000 at $4.29 pre market.
I think you shoulda waited Investor. They tend to move it up in pre-market and tank it at opening bell. But you might get lucky since today is Friday aka selloff day. So they just might raise it a little over $4.30 and dump for the weekend.
Good Luck though Posted by invester on :
quote:Originally posted by Lootcifer:
quote:Originally posted by invester: Just picked up 1000 at $4.29 pre market.
I think you shoulda waited Investor. They tend to move it up in pre-market and tank it at opening bell. But you might get lucky since today is Friday aka selloff day. So they just might raise it a little over $4.30 and dump for the weekend.
Good Luck though
]
It had a major sell off yesterday. The market cap is only $115m. I think it goes higher today. "I hope" Posted by BooDog on :
At Siga Technologies’ Corvallis research labs, Eric Stavale works on a possible treatment for the Dengue virus. Siga got a big cash infusion last week after announcing progress on an experimental smallpox treatment.
Siga Technologies finds quick payoff from test of smallpox remedy
By BENNETT HALL Gazette-Times business editor
It’s been a long and bumpy road, but the finish line may be in sight for Siga Technologies in its journey toward profitability.
Like many — if not most — small drug-discovery companies, Siga has burned through millions of dollars and posted year after year of losses as it tried to bring a developmental treatment to market. After a successful animal trial announced last week, however, the company could be on the verge of scoring a major coup with the first effective treatment for smallpox.
“In the biodefense area, smallpox is the number one concern, and we would expect this is going to be our big product,” said Dennis Hruby, Siga’s chief scientific officer and a microbiology professor at Oregon State University.
Smallpox was eradicated in nature 30 years ago but is considered a potential terrorist threat, and no proven treatment for the deadly virus exists. The Defense Department and other federal agencies funded the latest test, conducted on monkeys at a secure Centers for Disease Control facility in Atlanta.
Siga claims its drug, a once-daily pill called Siga-246, showed “100 percent protection” against the smallpox virus, both before and after exposure. The drug previously passed a human safety trial.
Additional tests are needed before the company can request approval from the Food & Drug Administration, but the Defense Department is footing the bill with a $16.5 million grant.
The news of a successful test triggered a financial windfall for Siga, which employs 50 people at its Corvallis research labs.
On Wednesday, the day the test results were announced, the company’s stock price more than doubled, shooting up to $4.54 a share after languishing at around $1 for most of the last year.
On Thursday, the company completed a $9 million private stock placement with some of its longtime institutional investors. Five hedge funds — Iroquois Master Fund, Cranshire Capital, Omicron Master Trust, Rockmore Investment Master Fund and Smithfield Fiduciary — bought the issue, consisting of 2 million shares of common stock at $4.54 a share. They also received warrants for an additional 1 million shares exercisable at $4.99 a share.
“It gave us the opportunity to bring in some cash quickly at a nice price,” said chief financial officer and acting CEO Tom Konatich, who’s been with the biotech firm for eight years. “Our balance sheet right now is about as strong as it’s been during my tenure.”
The stock placement caps a resurgence for Siga, which had entered a merger agreement last spring with an East Coast biotech company and faced delisting from the Nasdaq exchange this summer as its market capitalization slipped.
Now, with its cash reserves recharged and a smallpox drug marching toward approval, the merger is off and Siga is on the rebound.
“Siga’s a significantly different company today than it was in February and March,” Konatich said by phone from the company’s New York headquarters Friday. “We will be lobbying and negotiating with various agencies of the federal government for a sale of the drug.”
Konatich declined to speculate on when a deal to supply the drug might be reached or what it might be worth to Siga. But he did say that various industry estimates make it clear that the potential market for smallpox treatments is a lucrative one.
“It’s in the hundreds of millions of dollars, if not more,” he said.
Other potential markets await overseas, particularly in Europe. Hruby has been invited to Geneva to make a presentation to the World Health Organization’s advisory council, which he hopes will help spread the word about Siga’s research.
Hruby said Siga-246 can treat monkeypox and related viral diseases, and the firm is also pursuing drug candidates for a range of other exotic viruses.
“There’s two things: There’s biodefense, and there’s emerging diseases,” Hruby said. “Hopefully, we’ll never need it for biodefense. But it’s nice to have a drug like this on the shelf.”
Bennett Hall is the business editor for the Gazette-Times. He can be reached at 758-9529 or bennett.hall*lee.net.
Posted by Jo4321 on :
Biotech News: Analysis of SIGA Technologies Inc Nice news: Up nearly 12% ($3.75)
11:07a ET November 7, 2006 (Comtex) Analysis of SIGA Technologies Inc (NASDAQ: SIGA)
Say "ahhh" instead of "ow!" If development-stage SIGA Technologies has its way, painful vaccinations could become a thing of the past. The company is working on technology to administer vaccines directly through the mucus-lined surfaces -- mouth, nose, lungs, and gastrointestinal and urogenital tracts -- that are the usual entry points for most infectious agents. It focuses on vaccines, novel anti-infectives, and antibiotics for infectious diseases; its lead candidates are vaccines for bio-defense. In 2006 SIGA made breakthrough progress on a smallpox treatment, which completely prevented the disease in preliminary primate trials. The advancement led to funding from the National Institutes of Health.
Shares were up 10% after leading drug was shown to be successful.
BellwetherReport.com is a leading online research firm for international investors looking to get an edge over their portfolio. Investors seeking the most up to date information on SIGA Technologies Inc are invited to sign up for a free complimentary subscription to www.bellwetherreport.com. No credit card needed!
It was Siga Technologies Inc.'s turn to shine Wednesday, as shares jumped on news that the biotechnology company's leading drug was shown to be successful in protecting against smallpox, considered a bioterror threat.
Siga said SIGA-246 prevented symptoms when administered at the same time as the virus and 24 hours after exposure of the virus, in a government-funded study on monkeys.
Shares leapt $2.57, more than doubling in price, to close at $4.54 Wednesday on the Nasdaq. Heavy trading reached a volume of 39.3 million shares, more than 40 times the stock's average.
On Thursday, Siga announced it would sell 2 million shares for $4.54 per share, for a total of about $9 million, plus an additional 1 million warrants.
The stock continued to trade heavily and remained above $4 until Friday afternoon, ending the week at $3.92.
More information on SIGA Technologies Inc available in the members section of www.BellwetherReport.com.
To review research on SIGA Technologies Inc as well as many more exciting articles we encourage you to visit www.bellwetherreport.com. You can find these reports under the "Today's Articles" section. No credit Card Needed!!
The Bellwether Report will continue to research the small cap markets to bring you exciting opportunities!! If you are interested in receiving more information on these small cap opportunities and other features of our site, feel free to sign up for a complimentary subscription to the #1 online investment tool www.bellwetherreport.com.
Companies looking to advertise with Bellwether Report should email jlee*bellwetherreport.com with the subject line (Advertising).
All material herein was prepared by the Bellwetherreport.com, (Bellwether) based upon information believed to be reliable. The information contained herein is not guaranteed by Bellwether to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bellwether is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Bellwether may receive compensation in cash or shares from independent third parties or from the companies mentioned.
Bellwether's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value.
Bellwether will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bellwether undertakes no obligation to update such statements.
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info*m2.com.
Posted by Repoman75 on :
Almost back to $4... crap, another pick I screwed up.
Posted by Repoman75 on :
Up $1 today... damnit!
Posted by Jo4321 on :
There's still time. Didn't you once say you thought this would go to $7.00?
Jo
Posted by Repoman75 on :
Yeah, and it probably will too..
Posted by Lootcifer on :
Good old SIGA, there she goes today again. Missed this one. Hope you didn't Repo
Posted by Repoman75 on :
Missed it. I'm slacking lately.
Posted by Lootcifer on :
Press Release Source: SIGA Technologies, Inc.
SIGA Passes Another Milestone with Smallpox Drug SIGA-246 Thursday November 9, 1:17 pm ET
NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today the successful results of two independent primate trials of its smallpox drug SIGA-246. Last month, SIGA announced that SIGA-246 provides complete protection against human smallpox virus in nonhuman primates. The current trials involve infection with high doses of monkeypox virus, which may be lethal in primates if left untreated. SIGA-246 again afforded complete protection against disease symptoms. As with the primate trial last month and the human safety trial announced earlier this year, the current trials also demonstrate that SIGA-246 should be safe as well as effective.
ADVERTISEMENT The first monkeypox virus study was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) and conducted at the Lovelace Respiratory Research Institute in Albuquerque, NM. In this study, all monkeys in the two groups receiving SIGA-246 (different dosages) were completely protected from disease.
The second study was conducted at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and was funded by the Department of Defense's Defense Threat Reduction Agency under the supervision of Dr. John Huggins, Chief of the Viral Therapeutics Branch. In the second study, two groups of nonhuman primates received SIGA-246 orally starting either one day post-infection or three days post-infection. Again both treatment groups were completely protected from disease.
"Taken together with the recent breakthrough results from the smallpox virus study, the data continue to support the use of SIGA-246 as the first drug available to prevent and treat disease caused by pathogenic poxviruses without significant side effects," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. He added, "These are very important results for two reasons. First, in many respects monkeypox infections in non-human primates are more aggressive than infection with smallpox virus (normally a human pathogen), so protection by SIGA-246 represents a higher hurdle. Second, SIGA will likely use SIGA-246's performance against monkeypox infection in monkeys, along with the results in all of the several animal species tested to date, to satisfy FDA's efficacy requirements, so success here bodes well."
SIGA previously announced that SIGA-246 has been shown to be safe to administer to humans as a once-a-day pill. SIGA-246 has also demonstrated 100% disease protection in several mouse models of infection, which results SIGA will use, along with results from additional tests yet to be completed, to fulfill the U.S. Food and Drug Administration's "Animal Efficacy Rule." In December 2005, the FDA granted "fast-track" status to SIGA-246.
The Department of Homeland Security has designated smallpox a "material threat" to our national security, so SIGA-246 will be eligible for purchase for the Strategic National Stockpile under Project Bioshield.
In addition to smallpox, SIGA has antiviral programs targeting other Category A viral pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and LCM), flaviruses (Dengue), and the filoviruses (Ebola and Marburg), each of which presents a substantial, unmet medical need.
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA is a leading company in the discovery of pharmaceutical agents to fight emerging pathogens. SIGA leverages its proprietary technologies through multiple strategic partners, including the National Institutes of Health and TransTech Pharma, Inc. For more information about SIGA, please visit SIGA's Web site at www.siga.com.
About the National Institute of Allergy and Infectious Diseases (NIAID)
NIAID, an institute within the U.S. National Institutes of Health, conducts and supports research to study the causes of allergic, immunologic and infectious diseases, and to develop better means of preventing, diagnosing and treating these illnesses. NIAID is headquartered in Bethesda, Maryland.
About the Defense Threat Reduction Agency
The Defense Threat Reduction Agency (DTRA) is an agency of the U.S. Department of Defense that safeguards America and its allies from weapons of mass destruction by providing capabilities to reduce, eliminate, and counter the threat, and mitigate its effects. DTRA headquarters is located at Fort Belvoir, Virginia, and it also operates field offices worldwide. The DTRA has identified an orthopox therapeutic as a critical need in its ongoing threat reduction efforts.
About the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a critical role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Material Command.
The information contained in this press release does not necessarily reflect the position or policy of the U.S. government, and no official endorsement should be inferred.
Forward-looking Statements
This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.
Contact:
SIGA Technologies, Inc. Thomas N. Konatich, 212-672-9100 Chief Financial Officer & Acting CEO
Source: SIGA Technologies, Inc.
Posted by Jo4321 on :
Story hitting the AP now!
AP Siga: Studies Show Smallpox Drug Is Safe Thursday November 9, 2:41 pm ET Siga Pharamceuticals Says 2 Federal Studies Show Smallpox Drug Is Safe and Effective
NEW YORK (AP) -- Biotechnology company Siga Technologies Inc. said Thursday results from two independent studies of its smallpox drug show that it is safe and effective. The trials were conducted by the National Institute of Allergy and Infectious Diseases and the U.S. Army Medical Research Institute of Infectious Diseases. They focused on primates that had high levels of monkeypox infection, which can be fatal if left untreated. In both studies, the subjects were completely protected from the disease.
The study validates a previous study, the company said, in which the drug candidate provided complete protection against human smallpox in non-human primates.
Studies have shown that the treatment drug is safe to administer to humans in a once-a-day pill form. The drug, called Siga-246, has been granted Fast-Track status by the Food and Drug Administration.
Shares of Siga rose 14 cents, or 3.8 percent, to $4.03 in afternoon trading on the Nasdaq. The stock has traded between 86 cents and $5.50 over the last 52 weeks.
Posted by Lootcifer on :
Press Release Source: SIGA Technologies, Inc.
SIGA Announces $2.3 Million in New Contracts with the U.S. Air Force Friday November 10, 7:30 am ET
NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) today announced receipt of two contracts from the U.S. Air Force for a total of $2.3 million. SIGA received a one-year, $1.4 million contract with the Air Force Medical Service for the development of counter-measures against important potential biowarfare pathogens, the Dengue viruses, and other water-related viral agents. SIGA also received a one-year, $900,000 contract to aid the USAF Special Operations Command (USAFSOC) in its development of specific anti-viral agents, focusing on orthopoxvirus targets distinct from the target that is the focus of SIGA-246, the Company's lead smallpox drug.
ADVERTISEMENT Click here to find out more! "We appreciate the opportunity to continue the development of these critical biological defense capabilities with our colleagues from the Air Force," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA.
Dengue fever and Dengue hemorrhagic fever are acute febrile mosquito-borne diseases caused by one of four closely related virus serotypes of the genus Flaviviridae. The two diseases affect tens of millions of people worldwide every year and present a biodefense threat in the U.S. Currently, there is no approved drug or vaccine against Dengue, leaving troops vulnerable overseas and in areas affected by flooding.
SIGA recently announced a breakthrough in its SIGA-246 program with the successful completion of a preliminary primate trial in which the drug completely prevented smallpox disease.
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).
For more information about SIGA, please visit SIGA's Web site at www.siga.com.
Forward-looking Statements
This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.
Contact:
SIGA Technologies, Inc. Mr. Tom Konatich, 212-672-9100 CFO/Acting CEO
Source: SIGA Technologies, Inc.
Posted by Jo4321 on :
Nice news! Up a little, but I'm surprised this isn't flying.
Jo
Posted by Stefan on :
That SIGA 1.4m contract was out over a week ago, they just took their sweet time PRing it. It was nice to play it twice. Posted by Jo4321 on :
Posted on the-s-t-r-e-e-t.com
Siga Gets Air Force Pact
By Althea Chang TheStreet.com Staff Reporter 11/10/2006 2:56 PM EST
Siga Technologies (SIGA - commentary - Cramer's Take - Rating), a developer of antiviral medications, said it has received contracts from the Air Force worth $2.3 million. Under one contract valued at $1.4 million, Siga will develop counter-measures against potential biowarfare pathogens, the Dengue viruses and water-related viral agents for the Air Force Medical Service.
The company also received a one-year contract worth $900,000 to aid the Air Force Special Operations Command in developing antiviral agents.
Dengue fever and Dengue hemorrhagic fever are serious mosquito-borne diseases for which there are no approved drugs or vaccines. As a result, U.S. troops are vulnerable overseas and in areas affected by flooding, Siga says.
Shares were up 6.3% to $4.21 Friday.
Posted by Ace of Spades on :
I think these deals in the past few months...Are only shadows of things to come.
Posted by Mortimer on :
Olay! Found some support at 3.25ish Me thinks need more volume.
Posted by Jo4321 on :
*DJ Siga Technologies: Smallpox Drug Has 7 Yrs Exclusivity
(MORE TO FOLLOW) Dow Jones Newswires
12-20-06 1430ET
Copyright (c) 2006 Dow Jones & Company, Inc.
Posted by Jo4321 on :
Up 26% and going....
FDA Approves Orphan Drug Designation for SIGA's Smallpox Drug, SIGA-246 2:30 p.m. 12/20/2006 Provided by
The Designation is for Both Treatment and Prevention of Smallpox NEW YORK, Dec 20, 2006 (BUSINESS WIRE) -- SIGA Technologies, Inc. (SIGA) announced today that the Office of Orphan Products Development (OOPD) of the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to SIGA-246, SIGA's smallpox drug, for the prevention and treatment of smallpox. In December 2005, the FDA awarded SIGA-246 fast track status to expedite the drug's review.
Orphan Drug designation will entitle SIGA to seven years of marketing exclusivity in the United States if SIGA-246 becomes the first drug of its kind to obtain marketing approval from the FDA. Historically, the approval time for orphan products as a group has been considerably shorter than the approval time for other drugs.
"This is an important step in bringing SIGA-246 to market. The drug has made significant progress since the approval of its Investigational New Drug application just a year ago. In July 2006, we successfully completed the first planned human clinical safety trial, and, in October, the drug demonstrated 100% protection against human smallpox virus in a primate trial. We believe that SIGA-246 holds great promise and will be the first drug available to prevent and treat the disease without significant side effects," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA.
Smallpox has been designated by the Department of Homeland Security as a "material threat" to our national security, qualifying SIGA -246 for purchase for the Strategic National Stockpile under Project Bioshield. Currently, there is no effective and safe smallpox therapy available without the risk of significant complications, and the U.S. government has expressed strong interest in the development of novel smallpox therapies. Existing techniques to prevent or ameliorate smallpox have unacceptably high rates of complications, including encephalitis, myocarditis and death, and can take days or weeks to confer protection.
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). SIGA's product development programs also emphasize the increasingly serious problem of drug resistant bacteria.
For more information about SIGA, please visit SIGA's Web site at www.siga.com .
Forward-looking Statements
This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov . Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.
SIGA Technologies, Inc. Tom Konatich, 212-672-9100 Chief Financial Officer & Acting CEO
Copyright Business Wire 2006 ********************************************************************** As of Saturday, 12-16-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 09-27-2005 for SIGA * $1.25. For more information on Comtex SmarTrend Alert, contact your market data provider or go to www.CSTADirect.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright 2004-2006 Comtex News Network, Inc. All rights reserved.
Posted by RichBy26 on :
in at 3.40!
Posted by Mortimer on :
I exited at 2.87 last monday Posted by RichBy26 on :
I would buy back in, this thing is trying to explode. The volume is unreal...
Posted by Jo4321 on :
quote:I exited at 2.87 last monday
Mort! That's my job!
Jo
Posted by Mortimer on :
quote:Originally posted by Jo4321:
quote:I exited at 2.87 last monday
Mort! That's my job!
Jo
I think you called in sick that day. Posted by Repoman75 on :
Could be a gapper in the morning... but it always drops after a few days, so be prepared to flip.
Posted by RichBy26 on :
$4 coming...
Posted by Jo4321 on :
Up over a buck now.
Jo
Posted by RichBy26 on :
This news is really BIG, from th PR
"Orphan Drug designation will entitle SIGA to seven years of marketing exclusivity in the United States if SIGA-246 becomes the first drug of its kind to obtain marketing approval from the FDA. Historically, the approval time for orphan products as a group has been considerably shorter than the approval time for other drugs. "
The DOD sees small pox as a major threat, that means huge contracts would be awarded if this thing pulls through. In the short term, Repo is dead on, look for a gap tomorrow but then look to flip. These things almost always come back to earth.
Posted by pick em low on :
Sigger? Don't even know her!
$4's tomorrow though Orphan drug status isn't that big a deal..... day traders will whack this for tomorrow at least.... and it moves easy..... maybe $5 tomorrow in at 3.58 wasn't quick enough can't sell till tomorrow or my acct will get marked as a daytrader.... damn
Posted by RichBy26 on :
$4 !!!!
Posted by pick em low on :
keep posting I shut off my acct! I can't watch cause I can't sell I hope 3:45 it rockets It should nothing else is doing great today
Posted by Jo4321 on :
$4.15
Posted by pick em low on :
thx I turned it back on..... :-)
Posted by RichBy26 on :
pick em low, this thing is going to fly, that news was very big and a lot of people know it. This is not your average daytraders making this fly, over 6 million shares traded already, that's big money coming in and we're still moving up 4.16 now. $5 is very possible IMO today
Posted by pick em low on :
Great.... that would be nice.......
Posted by pick em low on :
AH.... I see it was above $4 before anyway.... it should easily hold that......
Posted by Jo4321 on :
quote: I think you called in sick that day.
No worries. I did sell JSDA today at $10.25 and now it is up to $10.63. I still got IT. ARGHHHHH!!!
Jo
Posted by pick em low on :
burp ahhhhhhhhhhh
Posted by RichBy26 on :
HOD, this thing is a monster!
Posted by RichBy26 on :
Look at the volume pouring in, unreal...
Posted by Jo4321 on :
Volume 8 million!
Jo
Posted by pick em low on :
4.27
Posted by pick em low on :
Gimme five dolla to make u holla!
Posted by Repoman75 on :
This stock is built to run on PR releases...
Posted by RichBy26 on :
Only the 3 of us playing this? too bad...
Posted by Jo4321 on :
Repo, remember when you said this could be the next FRPT?
LOL
Jo
Posted by Repoman75 on :
quote:Originally posted by Jo4321: Repo, remember when you said this could be the next FRPT?
LOL
Jo
Wouldn't be suprised... Gov't contracts = $$$
Posted by RichBy26 on :
WOW, 10M in volume with 30min to go!
Posted by Repoman75 on :
Gapper tomorrow...
Posted by Jo4321 on :
Up $2.00!
Posted by RichBy26 on :
quote:Originally posted by RichBy26: pick em low, this thing is going to fly, that news was very big and a lot of people know it. This is not your average daytraders making this fly, over 6 million shares traded already, that's big money coming in and we're still moving up 4.16 now. $5 is very possible IMO today
Let's see if my $5 today prediction comes to light!
Posted by pick em low on :
4.87 lol it's going too fast needs to cross $5 just before 4pm
Posted by Jo4321 on :
quote: Let's see if my $5 today call comes to light!
Don't jinx it now.
Posted by Repoman75 on :
Done for today, but gapper tomorrow.
Posted by Jo4321 on :
Hope you are right about that Repo, cause the sad thing is even with the spectacular run, I'm barely in the green because I bought it so high.
Jo
Posted by pick em low on :
it will run last 15 min some
Posted by Livinonklendathu on :
38% fib retrace is around 4.06.
Posted by pick em low on :
I'm under $4.06 so I guess I'm ok?
Posted by Livinonklendathu on :
But 4.40 is pretty good support for now, intraday
Posted by Jo4321 on :
Volume 13 million heading to the close
Posted by Repoman75 on :
Typical gapper pattern... daytraders leave, causing a drop, and now people are loading up for the morning. Then daytrader re enter in the AM>
Posted by pick em low on :
told ya up in last 15 min :-)
Posted by Jo4321 on :
Man, it wants $5.00.
Posted by RichBy26 on :
!!!!
Posted by Jo4321 on :
$5.00!
Well, I guess all the $5.00 sells are going to hit now and take it down a bit.
Posted by pick em low on :
yahooo
Posted by Kevin Bailey on :
holy sheeit! I was SO close to pulling the trigger when it pulled back to the 4.40s. Oh well. Congrats to all who are in this one!
Posted by Livinonklendathu on :
Support 4.82 / 4.40 and 38% fib now 4.33
Posted by RichBy26 on :
WOW, great close, only a few cents short of $5!!should gap nicely tomorrow!
Posted by Repoman75 on :
Just get ready to flip...
Posted by Kevin Bailey on :
B/A at 4.83x4.85 AH
Posted by pick em low on :
BBAAAAAA sheep for Bid Ask
Posted by Kevin Bailey on :
up to 4.90x4.91 ... it looked like they tried to "cool it off" a bit by spreading the B/A out to like .06, but the traders would have none of it, and kept pushing the MMs hard.
Posted by RichBy26 on :
close of 4.95 is what matters!!
Posted by pick em low on :
last time it shot up was on 40m volume it looks like..... given news was at 2:30 I guess it's on pace for higher than that.....
Posted by pick em low on :
this could rise a while.... or if it drops I'm hoping it would not be too hard.... it took 2 months for it to drop 4.50 to 2.70 not bad....
Posted by Livinonklendathu on :
The last pop it gapped open from 1.97 to 4.95 and it killed it.
Posted by pick em low on :
killed it down?
Posted by Livinonklendathu on :
Yea it opened at 4.95 and ran up to 5.50 and then downhill from there - different this go as we had news during the day. The last go was just to much of a gap.
Posted by pick em low on :
maybe there will be more news..... never know
Posted by Jo4321 on :
Good morning! Something to read pre-market. Report from back in October. Their 12-month target for SIGA is $10.20
morning gang, let's hope for another strong day!
Posted by RichBy26 on :
by looking at the L2's my guess is we see a small retrace at open, then a steady climb mid-morning through mid-afternoon, then a sell off EOD. That's my guess anyway, but if your here for the long term this is a definite winner!
Posted by Jo4321 on :
Well, my stop loss hit. Guess I'll miss out on the fun unless I decide to rebuy.
Yesterday morning I was down 33% in this, so I guess I'm satisfied that I ended slightly green.
Jo
Posted by Fuzzy1018 on :
will go back up imo
Posted by Fuzzy1018 on :
gap filled? should move up; huge news out yest. at 2pm
Posted by Jo4321 on :
The news from yesterday has been played out when it went to $5.15 yesterday. Now the "sell on news" crowd is here. Could be a good entry point below $4.00.
Jo
Edited to add: Well, darn as soon as I mentioned trying to get in below $4, it reversed from $4.02 to $4.16
I have that kind of effect on stocks.
Posted by Fuzzy1018 on :
selloff is done imo; may move up
Posted by RichBy26 on :
I'm looking to re-enter next week, should have sold yesterday at $5, but sold today at 4.50, still a very nice gain!!
Posted by Repoman75 on :
Good move. It will drop into the $3's shortly.
Posted by RichBy26 on :
agreed, and at $3 this stock is a steal IMO. I'll be buying a large sum if it drops to that level
Posted by Fuzzy1018 on :
i say we go back over $5 today
Posted by pick em low on :
WTF why can't stuff just stay up..... this stock fell hard after a run in the past too..... I still think it should close over $4 if not that's a bad sign
damn it and it's a friday before holiday coming up... that's never good
Posted by Kevin Bailey on :
I think there's a pretty good possibility that this one settles in the low-to-mid 3's. Looking at yesterday's candle, there was a lot of trading action all the way up the candle, so there's still profit-taking that could be going on, as well as loss-cutting as well. I guess we'll see what happens.
Posted by Livinonklendathu on :
IMO they are selling into the runs - look at the filings / S-3 dates and the dates the news has been released and you will have your answer.
CURRENT PRICE 4.08, at resistance, 4 ± 0.16, type double, strength 10
RESISTANCE ABOVE None.
SUPPORT BELOW -11% at 3.63 ± 0.14, type single, strength 2 -18.9% at 3.31 ± 0.13, type double, strength 10 -32.4% at 2.76 ± 0.11, type single, strength 3 -54.9% at 1.84 ± 0.07, type single, strength 3 -62.3% at 1.54 ± 0.06, type single, strength 5 -67.4% at 1.33 ± 0.05, type triple, strength 4 -70.3% at 1.21 ± 0.05, type single, strength 2 -72.5% at 1.12 ± 0.04, type double, strength 2 -74.8% at 1.03 ± 0.04, type triple, strength 4
Posted by Repoman75 on :
quote:Originally posted by Livinonklendathu: IMO they are selling into the runs - look at the filings / S-3 dates and the dates the news has been released and you will have your answer.
Bingo, give this man a cigar.
Posted by Fuzzy1018 on :
nice
Posted by pick em low on :
WTF keep it above $4 goddamn shorts
Posted by Kevin Bailey on :
Actually, shorts covering positions provide nice little cushion spots for stocks that are dropping. It's when there are no short positions that buy to cover with profit that a stock can just plummet.
Posted by Repoman75 on :
It's not shorts, its people cashing in and the company diluting.. that is what makes this stock a flipper but not an investment yet. Sell it on the run, and then reload for the next PR.
Posted by pick em low on :
I still think shorting should be illegal How dare they sell something they don't own and exacerbate a drop..... keep it simple buy or sell
Posted by pick em low on :
Come on, the Dec 1 S3 is only 500,000 shares.... that's a tiny amount
quote:Originally posted by Repoman75:
quote:Originally posted by Livinonklendathu: IMO they are selling into the runs - look at the filings / S-3 dates and the dates the news has been released and you will have your answer.
You're talking about naked shorting, I think. There's a difference. In a true short, two parties are involved, just like in a buy. The person who loans the stock to the short seller (usually a broker) has to own the stock before they can loan it. So shorting is no more unethical than buying. You're just purchasing the right from an owner of the stock to sell them the stock at a given price. If the price moves against you, the person who loaned you the stock makes money, and if it moves for you, you make money. It's a simple proposition, and it's not unethical at all.
Posted by Repoman75 on :
Yes, but those type of PR's panic investors... therefore, more sell.
Posted by pick em low on :
As Woodsy Owl says.... give a hoot! Don't dillute! and they are not no other board even brings it up.... they all can't be dumb
Posted by pick em low on :
I just don't like shorting even though I've done it on occassion......
Posted by Kevin Bailey on :
I just don't see the difference between buying a stock when you think the stock price will rise, and shorting the stock when you think it will go down.
Posted by pick em low on :
mmmmmm it feels wrong cause u don't own it.... lets say a stock shoots up like this one..... cause people buy it.... it should only drop cause those SAME people sell it, not cause a bunch of clown shorts come in and say "it's too high" it's basically shorts borrowing the shares people just bought and selling them out from under you.... selling your own shares practically!
Posted by Kevin Bailey on :
What's the difference between a chart reader looking at a chart and making a long decision based upon his belief that the stock's price will rise, and the same chart reader looking at a chart and making a decision based on his belief that the price will fall?
Posted by pick em low on :
I give up
Posted by Kevin Bailey on :
Do you not see my point, PEL? Or do you see it, and you just choose to hate shorters anyway?
Posted by Repoman75 on :
He hates shorters because he's down 10%..ahaha.
Posted by Kevin Bailey on :
You might be right. I've just never seen the point of hating shorters. If I'm right about a stock, and they're wrong, they lose money. If they're right, and I'm wrong, they lose money. Simple as that.
Posted by Repoman75 on :
I hate naked shorters though... to short shares that do not exist gives an unfair advantage. I can't buy shares that don't exist.
Posted by Kevin Bailey on :
I would tend to agree with you there. I don't know a WHOLE lot about naked shorting, but aren't they taking a HUGE risk if it moves to the upside?
Posted by pick em low on :
I see your point do you see mine I feel raped when people sell something I bought and they don't even own it they borrow from people who do own it and sell their shares it's like stealing my shares from my acct and selling them
Posted by pick em low on :
bought at 3.58 and 4 so I'm doing fine for now
Posted by Repoman75 on :
quote:Originally posted by Kevin Bailey: I would tend to agree with you there. I don't know a WHOLE lot about naked shorting, but aren't they taking a HUGE risk if it moves to the upside?
Well, retail investors are, yes... however, if you're a hedge fund, and you are naked short and you have no intention to deliver the shares.. then no.
Posted by pick em low on :
shake down on small share blocks
Posted by Livinonklendathu on :
3.80 area is support.
Posted by Kevin Bailey on :
quote:Originally posted by pick em low: I see your point do you see mine I feel raped when people sell something I bought and they don't even own it they borrow from people who do own it and sell their shares it's like stealing my shares from my acct and selling them
If you're talking about NAKED shorting, I would agree with you. Since you're not, I don't. When a stock is sold short it takes two parties to make the transaction work. It's no different AT ALL than betting on a stock's upward move. Shorts actually provide cushion for a drop, as they cover their positions as the stock falls, providing price support at various levels. If there's no short interest in a stock, when it plummets, it PLUMMETS! See Circuit City for an example. There was little or no short interest in the stock at the $24-25 level, and when bad news hit, it plunged to about $19, without a breather. Shorts give the falling stock "waystations" of a sort, as shorts cover their positions, taking their profits, and providing natural buyers at levels where buyers would otherwise not be.
Posted by Kevin Bailey on :
premarket B/A is at 3.74x3.79, so this one could gap down a bit ...
Posted by Jo4321 on :
Did anyone pick up an JSDA when I mentioned in this thread Wednesday that I had sold it at $10.25? It got mentioned by Cramer yesterday and it's now 12.20. My timing is impeccable.
But looks like I may have made the right choice on selling SIGA when I did.
Jo Queen of Bad Timing
Posted by Repoman75 on :
Be happy you're an FRPT holder.. luck is not all that bad.
Posted by Kevin Bailey on :
This stock took a beating today, and it's not getting any better after hours ... 3.37x3.39
Posted by Kevin Bailey on :
Longer-term prospects for this stock?
Posted by Kevin Bailey on :
Tough to find a floor of support to allow for a genuine short-term play on this stock, IMO. That's why I was wondering what everyone thought of the longer-term prospects for it, and a potential entry-point for a 2-3 month play.
Posted by Jo4321 on :
I wasn't paying much attention on Friday, but this 8K came out. Guess this is what caused some of the selling:
Item 8.01. Other Events. On December 20, 2006, PharmAthene, Inc. ("PharmAthene") filed a complaint (the "Complaint") against SIGA Technologies, Inc. ("SIGA") in the Delaware Chancery Court. PharmAthene's complaint alleges that it has the right to license exclusively development and marketing rights for SIGA's drug candidate, SIGA-246, pursuant to, among other things, the recently terminated merger agreement between the parties. PharmAthene's complaint further alleges that SIGA failed to negotiate the terms of such license in good faith and otherwise failed to grant such license, and it seeks to compel SIGA to enter into such license and pay unspecified damages. SIGA believes that the complaint lacks merit and intends to contest vigorously the alleged claims.
Posted by Fuzzy1018 on :
running nicely today
Posted by a surfer on :
up 20%
Posted by Jo4321 on :
SIGA: Successful Teatment of Child w/Lead Smallpox Drug Candidate 09:28 a.m. 03/19/2007 Provided by
Ridgeland, MS, MAR 19, 2007 (EventX/Knobias.com via COMTEX) -- By Fain Hughes, fhughes*knobias.com
SIGA Technologies, Inc. (SIGA) announced that a toddler who inadvertently contracted eczema vaccinatum has been treated with ST-246, SIGA's lead smallpox drug candidate, pursuant to an Emergency Investigational New Drug Application (IND) granted by the FDA, and is now improving.
Due to the absence of smallpox disease in the general human population, the efficacy of ST-246 has been investigated in animals to date. However, the federal Centers for Disease Control and Prevention (CDC) was recently notified that a child had contracted eczema vaccinatum, a potentially deadly illness that can manifest with a generalized skin rash similar to smallpox, following accidental contact with an open skin lesion on a relative who had recently been vaccinated for smallpox using a live vaccinia virus vaccine. The patient developed late-stage manifestations of the disease, including hemorrhagic lesions, respiratory failure, shock and high viral loads in the blood. CDC facilitated communication between SIGA and FDA resulting in provision of ST-246 for the patient under an Emergency IND.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com
Knobias.com, LLC 601-978-3399 601-978-3675 info*knobias.com www.knobias.com/cmtx Posted by a surfer on :
What do you guys think this is going to do? I got in a while ago at around $3.
Posted by a surfer on :
might be time to peek at this again.
Posted by a surfer on :
SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 Tuesday May 15, 8:30 am ET
NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today the successful results of a proof of concept guinea pig trial of its lead Lassa fever virus drug, ST-193. ADVERTISEMENT
This study was conducted under Biosafety Level 4 conditions at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) by Dr. Kathleen Cashman under the supervision of Dr. Mary Guttieri, who has been working on various hemorrhagic fever viruses at USAMRIID for over 12 years. Strain 13 guinea pigs were challenged with a lethal dose of Lassa virus and treated with ST-193 once a day for 14 days. Administration with ST-193 resulted in significant reduction in mortality at the two doses tested, 80 mg/kg and 25 mg/kg (71% of the animals survived at the low dose), whereas all of the control animals and those treated with ribavirin succumbed to the disease within 20 days of the challenge. The disease course in these guinea pigs recapitulates what is seen in human Lassa fever infections, and SIGA expects that this model is one of the two animal models that will be required to fulfill the U.S. Food and Drug Administration's "Animal Efficacy Rule."
"This is a tremendous milestone for our research group," said Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer. "This study should provide the basis for advancing this lead candidate into IND-enabling activities in the near future."
Lassa virus, considered a hemorrhagic fever virus due to some of its prominent symptoms, is one type of arenavirus. Arenaviruses are potential biological weapons agents due to their ease of dissemination, person-to-person transmissibility, and potential to cause widespread illness and death. Creating and deploying antiviral drugs targeting arenaviruses will enhance national and global security by acting as a significant deterrent and defense against the use of arenaviruses as bioterror weapons. Six separate arenaviruses are classified as Category A pathogens by the Centers for Disease Control and Prevention (CDC) due to the great risk that they pose to public health and national safety. Lassa fever is both a current world health threat, as it is prevalent in parts of West Africa (the CDC reports estimates of as many as 300,000 new cases each year), and a bioterror threat, due to its previous history as an object of weaponization research. Signs and symptoms of Lassa fever typically occur 1-3 weeks after the patient comes into contact with the virus. These include fever, retrosternal pain (pain behind the chest wall), sore throat, back pain, cough, abdominal pain, vomiting, diarrhea, conjunctivitis, facial swelling, proteinuria (protein in the urine), and mucosal bleeding. Neurological problems have also been described, including hearing loss, tremors, and encephalitis.
The Implementation Plan for Chemical, Biological, Radiological, and Nuclear Threats released in April by the Department of Health and Human Services lists arenaviruses as one of the biologic threats for which they plan to purchase medical countermeasures.
Dr. Eric A. Rose, Chairman and Chief Executive Officer of SIGA, adds, "Progress on our Lassa fever virus drug demonstrates the robustness of our product pipeline and furthers our goal to develop safe and effective countermeasures against all of the Category A viral pathogens."
Development of this Lassa antiviral is supported by the National Institutes of Health (NIH), which awarded SIGA a $6.0 million grant in September 2006.
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA is a leading company in the discovery of pharmaceutical agents to fight emerging pathogens. SIGA leverages its proprietary technologies through multiple strategic partners, including the National Institutes of Health and TransTech Pharma, Inc. For more information about SIGA, please visit SIGA's Web site at www.siga.com.
About the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a critical role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.
The information contained in this press release does not necessarily reflect the position or policy of the U.S. government, and no official endorsement should be inferred.
Forward-looking Statements
This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the safety or efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products, and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, are set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.
Contact: SIGA Technologies, Inc. Dr. Eric A. Rose, 212-672-9100 Chairman and Chief Executive Officer info*siga.com or Cameron Associates Al Palombo, 212-245-8800 Ext. 209 Investor Relations al*cameronassoc.com
Posted by Mortimer on :
Been playing around with this still. Anyone know why the action today?
![[Big Grin]](biggrin.gif)
for Advanced Development of Protexia(R) ![[Smile]](smile.gif)
![[Wink]](wink.gif)
![[Cool]](cool.gif)
![[Roll Eyes]](rolleyes.gif)
![[Mad]](mad.gif)
![[Eek!]](eek.gif)
![[Frown]](frown.gif)